Surviving as he does under the most precarious circumstances, the hemodialysis patient often becomes depressed upon confronting the profound changes in his lifestyle and psycho-social-sexual functioning. Careful differential diagnosis and vigorous treatment are essential in optimizing the quality of his life.
Depression may be detected by screening rating instruments, by subtle medical, psychological, or behavioral changes, or by direct patient complaint. We will summarize the current status of depression in hemodialysis patients.
The initial compliant of the depressed hemodialysis patient may be one of depressed mood, fatiguability, decreased appetite or sense of taste, or loss of sexual desire or ability. The medical defferential diagnosis of such symptoms is complex. Chronic uremia is associated with peripheral neuropathy, anemia, pruritis, infections, malnutrition, and disorders of calcium metabolism (1) . Sexual dysfunction is common (2, 3, 4) . Food may be unappealing and taste acuity decreased (5, 6) . Psychological conflicts often center around dependency on the machine and center staff or family responsible for running it (7) and on the marginal existence between chronic illness and health with uncertain role expectations (8) . Levels of rehabilitation to normal work function are highly variable. Control of hypertension may require drugs with high risk of causing depression. Depression is correlated with pain perception and patients report various forms of pain associated with uremia and its treatment (9) . Fatigue is greater in patients with depression and long term dialysis (10) .
The physician facing the depressed hemodialysis patient must explore several issues: attitude toward hemodialysis and resulting change in lifestyle, additional medical problems, current medications, and personal and family history of affective disorder. Diagnosis and vigorous treatment of the depressed hemodialysis patient are essential, as this group is at high risk for hospitalization and death (11) .
Attitude toward hemodialysis varies as a function of the du ration of the treatment. Several stages have been described, including an initial «honeymoon» and a later disenchantment and discouragement, followed by longterm adaptation with denial of the significance of complications (12) . Many patients must come to accept a loss of work time or ability to work at all, loss of sexual desire and ability to perform adequately, loss of physical stamina, limitations in dietary intake and food enjoyment, and pain associated with inserting cannulas and revising shunts. Often the patient facing chronic illness has seen himself as emotianally independent or strong and will have great difficulty adjusting to the role of cooperative and grateful patient dutifully obeying the many demands made upon him by the hemodialysis regime. It is beyond the scope of this review to discuss the many medical complications of the hemodialysis patient. Nonetheless, these must be carefully assessed because anemia, hepatitis and other infections, and metabolic disturbances may all contribute to depression.
Review of the use of medications and alcohol is always indicated in evaluating a depressed patient. Reserpine, alphamethyldopa, clonidine, and beta-blockers are all well known to cause depression (13, 14) . Whenever possible, antihypertensives that do not cross the bloodbrain barrier should be substituted. The chronic use of opiates, minor tranquilizers (including both benzodiazepines and barbiturates), and phenothiazine or antihistamines for nausea or itching may all contribute to liethargy.
Personal and family history of affective disorder may be explored using the DSM-III criteria for major depressive discorder and manic disorder ( Table 1 , from ref. 15 ). The patient reporting a definite episode of mania is diagnosed as bipolar regardless of when the episode occurred; this fact may be overlooked, with unfortunate results when a depressed patient treated with tricyclic antidepressants suddenly emerges from his depression into a flagrantly euphoric or irritable stage of mania, with its accompanying excesses and denial of psychiatric or medical illness. The patient who has had definite episodes of major depression before developing endstage renal disease and who has never been manic is diagnosed as having (recurrent) major depression. Auditory hallucinations and delusions, usually congruent with the predominant mood, may accur in both mania and major depression and are not specific indicators of schizophrenia. The severely depressed patient may hear voices telling him to kill himself and feel guilty of terrible sins. The manic patient may feel that he is God's special messenger and capable of healing diseased kidneys as symptoms of grandiosity. The risk of acting on hallucinations, delusions, or suicidal thoughts is a major indicator for psychiatric consultation or hospitalization.
Family history of affective disorder is highly relevant because primary affective disorders have a definite genetic predisposition and drug response of the patient may be predicted by that of a successfully treated first degree relative. Several recently developed biological markers for melancholic depression, the dexamethasone suppression test, the REM sleep latency, and the TRH-TSH test, have not been standardized for medically ill patients and so may be uninterpretable in hemodialysis patients. Depression rating scales such as the Zung and Beck self-ratings and the Hamilton interview are useful in quantitating the severity of depression and its response to treatment but are not designed to give cut-off scores above which treatment is indicated (16). These scales may be used for routine screening purposes by nursing staff or social workers.
Once it is established that the patient meets the clinical criteria for major depression or bipolar affective disorder, or has most of the criteria plus a family history of one of these disorders, a drug trial is indicated. The treatment of choice for bipolar affective disorder is 110 lithium carbonate in doses adequate to obtain serum levels of .5 to 1.2 mEq/L. Lithium is almost entirely excreted by the kidneys but is readily dialyzable. Renal failure is a classic controindication to its use, but it has been reported that therapeutic lithium levels are easily obtained and well tolerated in hemodialysis patients with a dose of 600-900 mg given thrice weekly after dialysis treatment and serum level monitoring performed before dialysis treatments about once a week (17) . Signs of lithium toxicity include tremor, dysarthria, ataxia, somnolence, muscle twitching with hyperreflexia, and are associated with high serum levels especially in the elderly.
Tricyclic antidepressants may be chosen on the basis of response to a test dose of dextroamphetamine or methylphenidate if hypertension or arrhythmias do not preclude this. Antidepressant response to a single dose of dextroamphetamine 30 mg predicts subsequent imipramine response while antidepressant response to methylphenidate given acutely up to 30 mg twice daily predicts subsequent response to imipramine or desipramine (18, 19) . Amitriptyline in usual therapeutic doses of up to 200 mg was well tolerated in one study where long-term post-dialysis weight gain was noted as an unexpected clinical benefit (20) . Imipramine has been used by others successfully. Piasa tricyclic antidepressant levels are readly commercially available and should probably be routinely monitored especially for nortriptyline and desipramine which have therapeutic windows (21). Frequent side effects of first generation antidepressants include dry mouth, blurred vision, constipation, postural hypotension, and sedation (especially with amitriptyline and doxepin).
Second-generation antidepressants such as amoxapine, maprotiline, and trazodone may offer an advantage for the depressed hemodialysis patient as their cardiovascular and anticholinergic toxicity are less than those of imipramine and amitriptyline and their onset of action is sometimes reported as more rapid.
Any antidepressant trial should be continued at the appropriate plasma level, or maximum tolerated dose, for at least 2 to 3 weeks before deciding to change medications. If the first drug should fail to produce an adequate improvement, a second drug should be substituted. Serotonergic drugs include amitriptyline and trazodone, noradrenergic drugs include desipramine, imipramine, and maprotiline, while mixed effects are attributed to nortriptyline and amoxapine. Often a change from a serotonergic to a noradrenergic drug, or vice versa, will produce the desired improvement. If it does not, there is the possibility of potentiating antidepressant response by adding triiodothyronine 25 mcg/DAY (21) or therapeutic doses of lithium carbonate. It may be that lithium carbonate is a first choice drug for the bipolar depressed patient because, unlike tricyclics, there is no risk of precipitating mania. Successful antidepressant treatment shou Id be continued for approximately 6 months before medication is tapered in an attempt to determine if it is still needed.
Psychological treatment of the depressed patient should almost always include the family members involved. There is a well-described pattern of reaction among home hemodialysis partners including anxiety, discouragement and frustration, enthusiasm, depression, and separation anxiety (22) . The spouse or children living with the patient may be active in transporting the patient to the hemodialysis center or performing home treatments. Their resentment of the amount of time, attention, financial resources, or lost income caused by hemodialysis may lead to a hostile home atmosphere in which the patient receives the subtle or overt message that the family would be better off if he were to die. Assessment of suicide risk must take the home environment into account and it is fully appropriate to ask the patient if he has feelings that the family would benefit from his death, if he has recently revised his will, and if he has plans for his own death. Approximately 3-6% of hemodialysis patients die of suicide or treatment termination and these figures may under-estimate actual rates because of apparently accidental death that are in fact suicides (23, 24) . Recent losses of selfesteem, relationships, sexual function, ability to work, or decline in physical health may all contribute to depression and suicidal intent.
The major focus of short-term psychotherapy must include the issues of illness and consequent losses and adjustments to the new dependent patient role. The primary care physician, nurse, or social worker on the dialysis unit will often assume this role as part of the overall care of the patient. When this occurs, it is essential that the caregiver recognize the importance with which the patient views him or her. The psychotherapeutic relationship may activate the patient's feelings from earlier periods in his life so that the doctor or nurse begins feeling like he has assumed a role like that of a parent taking care of a sick child. The caretaker, uncomfortable with this situation, may want to withdraw and avoid the clinging, needy patient. A consistent time period spent with the patient regularly may be of great value. Conversely, rejection or leaving the patient to spend more time with another patient or for a vacation may result in significant worsening of the medical or psychological condition of the patient who now feels the loss of attention as personal abandonment. It is essential to remember that depression colors the patient's entire outlook on life and, specifically, on the hemodialysis unit and its staff (25) .
The depressed hemodialysis patient presents a major challenge in diagnosis and treatment. Detailed medical and psychiatric evaluation are indicated to form the basis for a rational approach to biological and psychological treatment. Antidepressants and lithium carbonate may be used in this population with careful monitoring. Aggressive treatment is essential to the patient's wellbeing and may be extremely satisfying to the clinician.
